Zoledronic Acid Markedly Improves Bone Mineral Density for Patients with Monoclonal Gammopathy of Undetermined Significance and Bone Loss
James R. Berenson(Oncotherapeutics (United States)), Regina A. Swift(Institute for Myeloma & Bone Cancer Research), Siu‐Fun Wong(University of California, Irvine Medical Center), Olcay Batuman(SUNY Downstate Health Sciences University), Herbert L. Duvivier, Ori Yellin, Youram Nassir, Mehdi M. Moezi, Marshall S. Flam, Ralph V. Boccia(Center for Cancer and Blood Disorders), Donald Woytowitz
Cited by 70
Related Papers
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761
Assessment of thymic output in adults after haematopoietic stemcell transplantation and prediction of T-cell reconstitution
|The Lancet|2000|579
Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia
|New England Journal of Medicine|2010|425